Search

Your search keyword '"Yinyan Xu"' showing total 6 results
Start Over Author "Yinyan Xu" Publisher ferrata storti foundation
6 results on '"Yinyan Xu"'

2. Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia

Author

Atsushi Narita, Hideki Muramatsu, Yuko Sekiya, Yusuke Okuno, Hirotoshi Sakaguchi, Nobuhiro Nishio, Nao Yoshida, Xinan Wang, Yinyan Xu, Nozomu Kawashima, Sayoko Doisaki, Asahito Hama, Yoshiyuki Takahashi, Kazuko Kudo, Hiroshi Moritake, Masao Kobayashi, Ryoji Kobayashi, Etsuro Ito, Hiromasa Yabe, Shouichi Ohga, Akira Ohara, and Seiji Kojima

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Acquired aplastic anemia is an immune-mediated disease characterized by severe defects in stem cell number resulting in hypocellular marrow and peripheral blood cytopenias. Minor paroxysmal nocturnal hemoglobinuria populations and a short telomere length were identified as predictive biomarkers of immunosuppressive therapy responsiveness in aplastic anemia. We enrolled 113 aplastic anemia patients (63 boys and 50 girls) in this study to evaluate their response to immunosuppressive therapy. The paroxysmal nocturnal hemoglobinuria populations and telomere length were detected by flow cytometry. Forty-seven patients (42%) carried a minor paroxysmal nocturnal hemoglobinuria population. The median telomere length of aplastic anemia patients was −0.99 standard deviation (SD) (range −4.01–+3.01 SD). Overall, 60 patients (53%) responded to immunosuppressive therapy after six months. Multivariate logistic regression analysis identified the absence of a paroxysmal nocturnal hemoglobinuria population and a shorter telomere length as independent unfavorable predictors of immunosuppressive therapy response at six months. The cohort was stratified into a group of poor prognosis (paroxysmal nocturnal hemoglobinuria negative and shorter telomere length; 37 patients) and good prognosis (paroxysmal nocturnal hemoglobinuria positive and/or longer telomere length; 76 patients), respectively. The response rates of the poor prognosis and good prognosis groups at six months were 19% and 70%, respectively (P

Published
2015
Full Text
View/download PDF

3. GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies

Author

Xinan Wang, Hideki Muramatsu, Yusuke Okuno, Hirotoshi Sakaguchi, Kenichi Yoshida, Nozomu Kawashima, Yinyan Xu, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Shoji Saito, Yozo Nakazawa, Taro Masunari, Tadashi Hirose, Shaimaa Elmahdi, Atsushi Narita, Sayoko Doisaki, Olfat Ismael, Hideki Makishima, Asahito Hama, Satoru Miyano, Yoshiyuki Takahashi, Seishi Ogawa, and Seiji Kojima

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2015
Full Text
View/download PDF

4. Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia

Author

Hirotoshi Sakaguchi, Nobuhiro Nishio, Asahito Hama, Nozomu Kawashima, Xinan Wang, Atsushi Narita, Sayoko Doisaki, Yinyan Xu, Hideki Muramatsu, Nao Yoshida, Yoshiyuki Takahashi, Kazuko Kudo, Hiroshi Moritake, Kazuhiro Nakamura, Ryoji Kobayashi, Etsuro Ito, Hiromasa Yabe, Shouichi Ohga, Akira Ohara, and Seiji Kojima

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Predicting the response to immunosuppressive therapy could provide useful information to help the clinician define treatment strategies for patients with aplastic anemia. In our current study, we evaluated the relationship between telomere length of lymphocytes at diagnosis and the response to immunosuppressive therapy in 64 children with aplastic anemia, using flow fluorescence in situ hybridization. Median age of patients was ten years (range 1.5–16.2 years). Severity of the disease was classified as very severe in 23, severe in 21, and moderate in 20 patients. All patients were enrolled in multicenter studies using antithymocyte globulin and cyclosporine. The response rate to immunosuppressive therapy at six months was 52% (33 of 64). The probability of 5-year failure-free survival and overall survival were 56% (95% confidence interval (CI): 41–69%) and 97% (95%CI: 87–99%), respectively. Median telomere length in responders was −0.4 standard deviation (SD) (−2.7 to +3.0 SD) and −1.5 SD (−4.0 to +1.6 (SD)) in non-responders (P

Published
2014
Full Text
View/download PDF

5. Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia

Author

Asahito Hama, Nozomu Kawashima, Etsuro Ito, Shouichi Ohga, Seiji Kojima, Hiroshi Moritake, Kazuko Kudo, Ryoji Kobayashi, Akira Ohara, Nobuhiro Nishio, Yinyan Xu, Hirotoshi Sakaguchi, Atsushi Narita, Yusuke Okuno, Yoshiyuki Takahashi, Hiromasa Yabe, Hideki Muramatsu, Xinan Wang, Yuko Sekiya, Nao Yoshida, Masao Kobayashi, and Sayoko Doisaki

Subjects
Male, medicine.medical_specialty, Adolescent, Anemia, medicine.medical_treatment, Population, Hemoglobinuria, Paroxysmal, Hematopoietic stem cell transplantation, Gastroenterology, Telomere Homeostasis, Internal medicine, hemic and lymphatic diseases, medicine, Humans, Aplastic anemia, education, Child, Immunosuppression Therapy, education.field_of_study, business.industry, Anemia, Aplastic, Infant, Immunosuppression, Hematology, Articles, Telomere, medicine.disease, Prognosis, Child, Preschool, Immunology, Paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Female, business
Abstract

Acquired aplastic anemia is an immune-mediated disease characterized by severe defects in stem cell number resulting in hypocellular marrow and peripheral blood cytopenias. Minor paroxysmal nocturnal hemoglobinuria populations and a short telomere length were identified as predictive biomarkers of immunosuppressive therapy responsiveness in aplastic anemia. We enrolled 113 aplastic anemia patients (63 boys and 50 girls) in this study to evaluate their response to immunosuppressive therapy. The paroxysmal nocturnal hemoglobinuria populations and telomere length were detected by flow cytometry. Forty-seven patients (42%) carried a minor paroxysmal nocturnal hemoglobinuria population. The median telomere length of aplastic anemia patients was -0.99 standard deviation (SD) (range -4.01-+3.01 SD). Overall, 60 patients (53%) responded to immunosuppressive therapy after six months. Multivariate logistic regression analysis identified the absence of a paroxysmal nocturnal hemoglobinuria population and a shorter telomere length as independent unfavorable predictors of immunosuppressive therapy response at six months. The cohort was stratified into a group of poor prognosis (paroxysmal nocturnal hemoglobinuria negative and shorter telomere length; 37 patients) and good prognosis (paroxysmal nocturnal hemoglobinuria positive and/or longer telomere length; 76 patients), respectively. The response rates of the poor prognosis and good prognosis groups at six months were 19% and 70%, respectively (P

Published
2015

6. Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia

Author

Xinan Wang, Etsuro Ito, Seiji Kojima, Hideki Muramatsu, Nobuhiro Nishio, Nao Yoshida, Kazuko Kudo, Hiromasa Yabe, Hirotoshi Sakaguchi, Akira Ohara, Atsushi Narita, Sayoko Doisaki, Yoshiyuki Takahashi, Hiroshi Moritake, Kazuhiro Nakamura, Asahito Hama, Nozomu Kawashima, Ryoji Kobayashi, Shouichi Ohga, and Yinyan Xu

Subjects
Male, medicine.medical_specialty, Adolescent, Anemia, Gastroenterology, Telomere Homeostasis, Predictive Value of Tests, Internal medicine, medicine, Humans, Lymphocytes, Aplastic anemia, Child, medicine.diagnostic_test, business.industry, Hazard ratio, Anemia, Aplastic, Infant, Hematology, Articles, Telomere, medicine.disease, Confidence interval, Treatment Outcome, Predictive value of tests, Peripheral blood lymphocyte, Child, Preschool, Immunology, Female, business, Immunosuppressive Agents, Fluorescence in situ hybridization
Abstract

Predicting the response to immunosuppressive therapy could provide useful information to help the clinician define treatment strategies for patients with aplastic anemia. In our current study, we evaluated the relationship between telomere length of lymphocytes at diagnosis and the response to immunosuppressive therapy in 64 children with aplastic anemia, using flow fluorescence in situ hybridization. Median age of patients was ten years (range 1.5-16.2 years). Severity of the disease was classified as very severe in 23, severe in 21, and moderate in 20 patients. All patients were enrolled in multicenter studies using antithymocyte globulin and cyclosporine. The response rate to immunosuppressive therapy at six months was 52% (33 of 64). The probability of 5-year failure-free survival and overall survival were 56% (95% confidence interval (CI): 41-69%) and 97% (95%CI: 87-99%), respectively. Median telomere length in responders was -0.4 standard deviation (SD) (-2.7 to +3.0 SD) and -1.5 SD (-4.0 to +1.6 (SD)) in non-responders (P

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results